Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals
Okroj, Marcin LU ; Spiller, O Brad ; Korodi, Zoltan LU ; Tedeschi, Rosamaria ; Dillner, Joakim LU and Blom, Anna LU
(2007)
In Vaccine
25(48).
p.8102-8109
- Abstract
- Kaposi sarcoma-associated herpesvirus (KSHV) is the most important etiopathological factor of Kaposi's sarcoma (KS) and some specific types of malignant lymphomas. One of the viral lytic genes encodes the KSHV complement control protein (KCP), which functionally mimics human complement inhibitors. Although this protein provides an advantage for evading the complement attack, it can serve as target for adaptive immune response. Herein, we identified anti-KCP IgG antibodies in patients with KS and KSHV-related lymphomas. KCP-specific antibodies were only detected in sera of those patients who had high titres of antibodies against lytic or latent KSHV antigens. Complement control protein domain 2 (CCP2) was found to be the most immunogenic... (More)
- Kaposi sarcoma-associated herpesvirus (KSHV) is the most important etiopathological factor of Kaposi's sarcoma (KS) and some specific types of malignant lymphomas. One of the viral lytic genes encodes the KSHV complement control protein (KCP), which functionally mimics human complement inhibitors. Although this protein provides an advantage for evading the complement attack, it can serve as target for adaptive immune response. Herein, we identified anti-KCP IgG antibodies in patients with KS and KSHV-related lymphomas. KCP-specific antibodies were only detected in sera of those patients who had high titres of antibodies against lytic or latent KSHV antigens. Complement control protein domain 2 (CCP2) was found to be the most immunogenic part of the KCP protein. Furthermore, pre-incubation of KCP-expressing CHO cells with patient sera containing anti-KCP antibodies resulted in an increased complement deposition when incubated with human serum. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1138127
- author
- Okroj, Marcin
LU
; Spiller, O Brad
; Korodi, Zoltan
LU
; Tedeschi, Rosamaria
; Dillner, Joakim
LU
and Blom, Anna
LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Complement, Kaposi sarcoma, HIV, Lymphoma, Antibodies
- in
- Vaccine
- volume
- 25
- issue
- 48
- pages
- 8102 - 8109
- publisher
- Elsevier
- external identifiers
-
- pmid:17964697
- wos:000251472600002
- scopus:35748937347
- ISSN
- 1873-2518
- DOI
- 10.1016/j.vaccine.2007.09.046
- language
- English
- LU publication?
- yes
- id
- 14a4e471-2746-459b-b6be-95f412f803cf (old id 1138127)
- date added to LUP
- 2016-04-01 12:25:04
- date last changed
- 2022-01-27 03:27:28
@article{14a4e471-2746-459b-b6be-95f412f803cf,
abstract = {{Kaposi sarcoma-associated herpesvirus (KSHV) is the most important etiopathological factor of Kaposi's sarcoma (KS) and some specific types of malignant lymphomas. One of the viral lytic genes encodes the KSHV complement control protein (KCP), which functionally mimics human complement inhibitors. Although this protein provides an advantage for evading the complement attack, it can serve as target for adaptive immune response. Herein, we identified anti-KCP IgG antibodies in patients with KS and KSHV-related lymphomas. KCP-specific antibodies were only detected in sera of those patients who had high titres of antibodies against lytic or latent KSHV antigens. Complement control protein domain 2 (CCP2) was found to be the most immunogenic part of the KCP protein. Furthermore, pre-incubation of KCP-expressing CHO cells with patient sera containing anti-KCP antibodies resulted in an increased complement deposition when incubated with human serum.}},
author = {{Okroj, Marcin and Spiller, O Brad and Korodi, Zoltan and Tedeschi, Rosamaria and Dillner, Joakim and Blom, Anna}},
issn = {{1873-2518}},
keywords = {{Complement; Kaposi sarcoma; HIV; Lymphoma; Antibodies}},
language = {{eng}},
number = {{48}},
pages = {{8102--8109}},
publisher = {{Elsevier}},
series = {{Vaccine}},
title = {{Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals}},
url = {{http://dx.doi.org/10.1016/j.vaccine.2007.09.046}},
doi = {{10.1016/j.vaccine.2007.09.046}},
volume = {{25}},
year = {{2007}},
}